Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria

Status Completed

Clinical Trial Summary

Chlorproguanil-dapsone has been approved for the treatment of uncomplicated Plasmodium falciparum malaria in a number of countries across sub-Sahara Africa, and by the UK's Medicines and Healthcare products Regulatory Agency.

CDA is a combination of chlorproguanil, dapsone and artesunate, being developed in a public-private partnership with the Medicines for Malaria Venture (MMV), World Health Organisation (WHO-TDR) and academic partners from the London School of Hygiene and Tropical Medicine, University of Liverpool and the Liverpool School of Tropical Medicine as a treatment for acute uncomplicated P. falciparum malaria.

The combination of chlorproguanil-dapsone-artesunate (CDA) is being developed to supersede chlorproguanil-dapsone for the same indication, but the addition of an artemisinin derivative, artesunate, should provide additional population benefits over chlorproguanil-dapsone alone. The artemisinins have been demonstrated to rapidly reduce parasite load and have activity against the sexual stages of the P.falciparum lifecycle. The addition of a second agent to the chlorproguanil-dapsone combination should also protect against the selection of resistant strains of P.falciparum.

Artemether-lumefantrine is the only available fixed-dose Artemisinin-based Combination Therapy actually available and is considered as the gold standard for the treatment of P. falciparum malaria. This study will therefore aim to demonstrate the non-inferiority of the combination of CDA to artemether-lumefantrine in terms of efficacy at 28-days. The key secondary objectives will compare the Parasite Clearance Times (PCT) and the Fever Clearance Times (FCT) between CDA and artemether-lumefantrine.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00344006
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 3
Start date	June 2006
Completion date	August 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02329301` - Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia	N/A
Recruiting	`NCT01944189` - Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics	Phase 4
Terminated	`NCT01442168` - Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria	Phase 1/Phase 2
Completed	`NCT01325974` - Time to Become Negative of Three Rapid Diagnostic Tests for Malaria	N/A
Completed	`NCT00375128` - Sporozoite Challenge of Polyprotein Vaccinees	Phase 1/Phase 2
Terminated	`NCT00374205` - Randomized Trial on Effectiveness of ACTs in Ghana	Phase 4
Completed	`NCT04609098` - Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)	Phase 2
Completed	`NCT02851108` - Methylene Blue Against Falciparum Malaria in Burkina Faso	Phase 2
Completed	`NCT02434952` - Safety and Tolerability of Low Dose Primaquine	Phase 4
Terminated	`NCT02281344` - MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants	Phase 1
Completed	`NCT01213966` - Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection	Phase 2
Completed	`NCT00479206` - Artemisinin Resistance in Cambodia	N/A
Completed	`NCT00126906` - Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi	N/A
Completed	`NCT01019408` - Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan	Phase 4
Completed	`NCT00529867` - Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria	Phase 4
Completed	`NCT00137553` - The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children	Phase 4
Completed	`NCT02637128` - In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria	Phase 4
Completed	`NCT01222962` - Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers	Phase 1
Unknown status	`NCT00152204` - The Community Effectiveness of IPTi in Southern Tanzania	Phase 3
Terminated	`NCT00084240` - Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.